This biotech company develops a novel therapeutic strategy for chronic pain management. Their approach uses a Lipid antisense oligonucleotide to target a specific regulator in the dorsal root ganglion, modulating pain signaling pathways to provide relief for patients with complex and unbearable conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic pain affects a significant portion of the population, impacting daily activities and overall quality of life. Current pain management treatments, particularly opioids, often come with serious drawbacks such as addiction, cognitive impairment, and reduced efficacy over time. This leaves many patients with limited options for effective and safe pain relief, especially those undergoing treatments like chemotherapy that induce peripheral neuropathy.
Solution
Dolinnov is developing a novel therapeutic approach using Lipid Antisense Oligonucleotide (L-ASO) technology to target the FXYD2 protein, a regulator of the Na+/K+ ATPase pump, in the dorsal root ganglion (DRG). This precise targeting of FXYD2 modulates pain signaling pathways, offering a non-opioid alternative for managing both neuropathic and inflammatory pain. Dolinnov's proprietary L-ASO chemistry enhances cellular uptake and bioavailability while minimizing side effects, providing a more effective and safer solution for patients with severe and intractable pain. The therapy aims to enable patients to undergo necessary treatments, such as chemotherapy, without experiencing unbearable pain, thereby improving their quality of life and treatment adherence.
Target Audience
The primary target audience includes patients suffering from chronic neuropathic and inflammatory pain, particularly those with rare disorders and Chemotherapy-Induced Peripheral Neuropathy (CIPN), as well as oncologists and pain management specialists seeking safer and more effective treatment options.
Features
- Proprietary Lipid Antisense Oligonucleotide (L-ASO) technology for targeted pain management.
- Specific targeting of the FXYD2 protein in the dorsal root ganglion (DRG) to modulate pain signaling.
- Enhanced cellular uptake and bioavailability of L-ASO, minimizing potential side effects.
- Demonstrated efficacy in preclinical models for neuropathic and inflammatory pain, including Chemotherapy-Induced Peripheral Neuropathy (CIPN).
- Potential for multiple routes of administration.
- Non-opioid mechanism of action, reducing the risk of addiction and cognitive impairment.